TriangleDISEASE & TREATMENT SETTING
KEYTRUDA: metastatic cervical cancer with PD-L1 stated without a specific alteration after prior therapy
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] .
Broader topic: Cervical Cancer
- Source population
- Not part of this definition
- Disease extent
- metastatic
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- gene
- PD-L1
- alteration
- stated without a specific alteration
- status
- present
- prior therapy
- class
- after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authoriz
- status
- required
- derivation status
- source-attested
- derivation note
- Scoped from the FDA approved indication for KEYTRUDA (product label). Only dimensions stated in that wording are part of this definition.
- source wording
- KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] .
Study evidence for this setting
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice